You have 0 Articles Left This Month. Register Today for Unlimited Access.
Medicare’s spending on drugs to treat hepatitis C soared more than 15 fold from 2013 to 2014 as new breakthroughs came to the market, according to previously undisclosed federal data. The drugs cure the disease, but taxpayers are footing the bill.
This story was co-published with the Washington Post.
You have 0 complimentary articles left.
Register for free today to continue reading!
Already have an account? Sign in here.